Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

22
GlycoMimetics Stock Has Substantial Upside

2018-08-11 investorplace
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. It beat consensus estimates on earnings. Its cash position was at high enough levels to cover future operational needs. And the company announced a number of clinical studies that demonstrate it continues to develop treatments for cancer patients.
GLYC SRPT PFE EXAS

0
GLYC / GlycoMimetics, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
glyc_Current_Folio_10Q Table of Contents
GLYC

0
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-08-09 sec.gov
glyc_Current_Folio_8K UNITED STATES
GLYC

0
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-07-25 sec.gov
glyc_Current_Folio_8K UNITED STATES
GLYC

21
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-05-21 sec.gov
glyc_Current_Folio_8K no exhibits UNITED STATES
GLYC

20
GlycoMimetics' (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Good morning, and thank you all for joining the GlycoMimetics' call. At this time all participants are in a listen-only mode. [Operator Instructions]
GLYC

23
GLYC / GlycoMimetics, Inc. 10-Q (Quarterly Report)

2018-05-03 sec.gov
glyc_Current_Folio_10Q Table of Contents
GLYC

22
GLYC / GlycoMimetics, Inc. 8-K (Current Report)

2018-05-03 sec.gov
glyc_Current_Folio_8K UNITED STATES
GLYC

20
BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

2018-05-03 reuters
* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:
GLYC

23
GLYC / GlycoMimetics, Inc. DEF 14A

2018-04-13 sec.gov
glyc_Current_Folio_DEF14A SCHEDULE 14A INFORMATION
GLYC

26
GlycoMimetics: Buy This Dip

2018-04-04 seekingalpha
GlycoMimetics (NASDAQ:GLYC) is a clinical stage biotechnology company with two drug candidates that could gain FDA approval in 2019 and 2021, respectively. Recent developments, including the general decline in pharma stock prices, have made the dip in the price of GlycoMimetics a compelling buy. However, there are risks involved, notably the risk that, despite good preliminary data, one or both of the therapies in the pipeline will fail to generate passable Phase 3 trial data.
GLYC IBB PFE

20
GLYC / GlycoMimetics, Inc. 424B5 (Prospectus)

2018-03-21 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
GLYC

22
20
GLYC / GlycoMimetics, Inc. 424B5 (Prospectus)

2018-03-19 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
GLYC

GLYC: GlycoMimetics Analysis and Research Report

2018-05-07 - Asif

Overview GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. The company's proprietary glycomimetics platform is based on its expertise in carbohydrate chemistry and its understanding of the role carbohydrates play in key biological processes. Using this expertise and understanding, GlycoMimetics is developing a pipeline of proprietary glycomimetics designed to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. The company believe this represents an innovative approach to drug discovery to treat a wide range of diseases. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 38000Q102